Latest news with #BalaCynwyd
Associated Press
19-05-2025
- Business
- Associated Press
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
BALA CYNWYD, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847. There is no cost or financial obligation to you. TXNM Energy, Inc. (NYSE - TXNM) Under the terms of the agreement, TXNM Energy will be acquired by Blackstone Infrastructure for $61.25 per share in cash, reflecting a total enterprise value of $11.5 billion. The investigation concerns whether the TXNM Energy Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company's shareholders. Additional information can be found at Inozyme Pharma, Inc. (Nasdaq – INZY) Under the terms of the Merger Agreement, Inozyme Pharma will be acquired by BioMarin Pharmaceutical Inc. ('BioMarin') (Nasdaq – BMRN) for $4.00 per Inozyme Pharma share in an all-cash transaction for a total consideration of approximately $270 million. The investigation concerns whether the Inozyme Pharma Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company's shareholders. Additional information can be found at Servotronics, Inc. (NYSE American - SVT) Under the terms of the agreement, Servotronics will be acquired by TransDigm for $38.50 per share in cash, in a transaction valued at approximately $110 million. The investigation concerns whether the Servotronics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company's shareholders. Additional information can be found at Protagenic Therapeutics, Inc. (Nasdaq – PTIX) Under the terms of the Merger Agreement, Protagenic Therapeutics will be acquired by Phytanix Bio Inc. ('Phytanix') Ownership of the combined company will be approximately 35% for Protagenic Therapeutics stockholders and approximately 65% for Phytanix stockholders. The investigation concerns whether the Protagenic Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company's shareholders in the combined company. Additional information can be found at Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
Associated Press
19-05-2025
- Business
- Associated Press
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Landsea Homes Corporation (Nasdaq - LSEA), LENSAR, Inc. (Nasdaq - LNSR), AvidXchange Holdings, Inc. (Nasdaq – AVDX), FARO Technologies, Inc. (Nasdaq – FARO)
BALA CYNWYD, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847. There is no cost or financial obligation to you. Landsea Homes Corporation (Nasdaq - LSEA) Under the terms of the agreement, Landsea Homes will be acquired by New Home Co. ('New Home') for $11.30 per share in cash. The investigation concerns whether the Landsea Homes Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. For example, the deal consideration is below the 52-week high of $14.04 for the Company's shares. Additional information can be found at LENSAR, Inc. (Nasdaq - LNSR) Under the terms of the Merger Agreement, LENSAR will be acquired by Alcon for $14.00 per share in cash for each LENSAR share, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash, conditioned on achievement of 614,000 cumulative procedures with LENSAR's products between January 1, 2026, and December 31, 2027. The investigation concerns whether the LENSAR Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company's shareholders are receiving fair value for their shares. Additional information can be found at AvidXchange Holdings, Inc. (Nasdaq – AVDX) Under the terms of the agreement, AvidXchange Holdings will be acquired by TPG (Nasdaq – TPG) for $10.00 a share in cash in a transaction that values AvidXchange Holdings at $2.2 billion. The investigation concerns whether the AvidXchange Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Additional information can be found at FARO Technologies, Inc. (Nasdaq – FARO) Under the terms of the Merger Agreement, FARO will be acquired by AMETEK, Inc. (NYSE - AME) for $44 per share in cash. The investigation concerns whether the FARO Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of the Company's shareholders in the combined company. Additional information can be found at Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
CBS News
12-05-2025
- Health
- CBS News
New device helps patients cope with tinnitus, Pennsylvania audiologist says
A growing number of patients are turning to a new treatment for a condition that causes ringing in the ears. The device tricks the brain with a tickle to the tongue. Silence really is golden for Clara Flores. Her days used to be filled with the constant buzzing and ringing that comes with tinnitus, which affects 25 million Americans. "This ringing that you hate and can't stand ... you cannot turn it off," Flores said. "You get depressed, you get angry. Your relationships suffer." But the maddening noise is not a hearing problem, according to Bala Cynwyd audiologist Gail Brenner. "Tinnitus is a sound that we perceive in our ears or head that's internally generated by the brain," Brenner said. And now, for the first time, she says there's finally a treatment that works for most patients Lenire is an FDA-approved device that works with headphones and a tongue stimulator. The electrical pulses from the device "feel like bubbly Champagne," she said. "It's just a tiny little tingle, and that's all we need for the signal to transmit to the brain." Lenire costs $4,000 and isn't covered by insurance. It worked for Flores, who listened to the soothing sounds with the mouthpiece for 12 weeks — twice a day for half an hour. "It did magic to my brain," Flores said. The maker of Lenire says it works by retraining the brain not to hear the sounds from tinnitus that can be caused by loud noise, hearing loss and infections. "We're teaching the brain to not pay attention to the tinnitus," Brenner said. "It has been a game-changer." Flores thinks her tinnitus was caused by an infection, but she doesn't notice the buzzing anymore. "It doesn't bother me. I forget about it," Flores said. Her brain is refocused and noise-free now, giving her a new lease on life. Research on the Lenire device showed that about 80% of the people who tested it had significant improvements.
